Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the ...
PHOENIX — The oral medication resmetirom significantly improved liver stiffness and reduced portal hypertension in metabolic ...
Madrigal Pharmaceuticals sees rapid Rezdiffra sales growth with EU approval and long-term GLP-1 strategy. Learn why MDGL ...
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.
With the business potentially at an important milestone, we thought we'd take a closer look at Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) future prospects. Madrigal Pharmaceuticals, Inc., a ...
In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The ...
Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback